I—Cancer cachexia: pathophysiological mechanisms
- 30 April 1996
- journal article
- review article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 22 (2) , 192-196
- https://doi.org/10.1016/s0748-7983(96)90905-1
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Cancer cachexiaAnti-Cancer Drugs, 1993
- Interleukin-6 and its relation to inflammation and diseaseClinical Immunology and Immunopathology, 1992
- The Role of Prostaglandin E2 in Immune Suppression Following InjuryAnnals of Surgery, 1991
- Elevated Circulating Interleukin-6 Is Associated with an Acute-phase Response but Reduced Fixed Hepatic Protein Synthesis in Patients with CancerAnnals of Surgery, 1991
- Effect of low dose recombinant interleukin 2 plus indomethacin on mortality after sepsis in a murine burn modelBritish Journal of Surgery, 1990
- Cancer CachexiaAnnals of Surgery, 1988
- EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCERThe Lancet, 1987
- Tumors secreting human TNF/cachectin induce cachexia in miceCell, 1987
- Cachectin: More Than a Tumor Necrosis FactorNew England Journal of Medicine, 1987
- Mechanisms of immunosuppression associated with severe nonthermal traumatic injuries in man: Production of interleukin 1 and 2Journal of Clinical Immunology, 1986